Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

AIDS

Volumn 17, Issue 7, 2003, Pages 1023-1028

  Pérez Olmeda, Mayte ^a   Núñez, Marina ^a   Romero, Miriam ^a   González, Juan ^b   Castro, Angeles ^c   Arribas, José Ramón ^b   Pedreira, José ^c   Barreiro, Pablo ^a   García Samaniego, Javier ^a   Martín Carbonero, Luz ^a   Jiménez Nácher, Inmaculada ^a   Soriano, Vincent ^a,d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d NONE   (Spain)

Author keywords

Antiretroviral therapy; Hepatitis C; HIV; Pegylated interferon; Ribavirin

Indexed keywords

AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; DIDANOSINE; PEGINTERFERON ALPHA2B; RIBAVIRIN; STAVUDINE; ZIDOVUDINE; ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LACTIC ACIDOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRIORITY JOURNAL; RELAPSE; VIRUS LOAD; WEIGHT REDUCTION; ADOLESCENT; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 0038555663     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305020-00011     Document Type: Article

References (28)

1. McHutchison J, Gordon S, Schiff E, Shiffman M, Lee V, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492.
2. Poynard T, Marcellin P, Lee S, Niederau C, Minuk G, Ideo G, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-1432.
3. Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
4. Zeuzem S, Feinman S, Rasenack J, Heathcote E, Lai M, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666-1672.
5. Manns M, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
6. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta S, Salfi M, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000; 32:647-653
7. Fried M, Shiffman M, Reddy R, Smith C, Marinos G, Goncales F, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N EnglJ Med 2002; 347:975-982.
8. NIH Consensus Development Conference Statement: Management of Hepatitis C 2002. Gastroenterology 2002; 123:2082-2099.
9. a with RBV for the treatment of chronic hepatitis C in HIV coinfection. In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [Abstract LB15].
10. Goelz J, Klausen G, Moll A. Efficacy and tolerance of therapy with IFN-alpha/RBV and peglFN-alpha/RBV in HIV-/HCV-coinfected IVDUs. In: XIVth World AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract MoPeB3258].
11. Perrone C, Carrat F, Bani S. RIBAVIC trial (ANRS HCo2): a controlled randomized trial of pegylated-interferon alfa-2b plus ribavirin versus interferon alfa2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients: preliminary results. In: XIVth World AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract LbOr16].
12. Rockstroh J, Schulz C, Mauss S, Klausen G, Voigt E, Gölz J. Pegylated interferon-alpha and ribavirin therapy for hepatitis C in HIV-coinfected patients: 24 weeks results. In: XIVth World AIDS Conference. Barcelona, Spain, 7-12 July 2000 [Abstract WePeB6025].
13. Hopkins S, Lyons F, Brannigan E, Mulcahy F, Bergin C. Tolerability of pegylated interferon and ribavirin in the HIV/HCV co-infected population. In: XIVth World AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract ThPeC7531].
14. Puoti M, Zanini B, Bruno R, Airoldi M, Rossi S, Roldan E, et al. Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected patients with HIV and HCV. HIV Clin Trials 2002; 3:324-332.
15. Ferenci P, Brunner H, Nachbaur K, Datz C, Gschhwantler M, Hofer H, et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001; 34:1006-1011
16. Lafeuillade A, Hittinger G, Chapadaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-281.
17. Kakuda T, Brinkman K. Mitochondrial toxic effects of ribavirin. Lancet 2001; 357:1803.
18. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B, Sogni R Mitochondrial toxic effects of ribavirin. Lancet 2001; 357:1803.
19. Poynard T, McHutchison J, Goodman Z, Ling M, Albrecht J. Is an 'à la carte' combination interferon alfa 2b plus ribavirin regimen possible for the first llne treatment in patients with chronic hepatitis C? Hepatology 2000; 31:211-218.
20. Martinot-Peignoux M, Marcellin P, Poureau M, Castelnau C, Boyer N, Poliquin M, et al. Pre-treatment HCV-RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology 1995; 22:1050-1056.
21. Soriano V, García-Samaniego J, Bravo R, González J, Castro A, Castilla J, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with HIV. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23:585-591.
22. García-Samaniego J, Soriano V, Castilla J, Bravo R, Moreno A, Carbó J, et al. Influence of HCV genotypes and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterol 1997; 92:1130-1134.
23. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in HIV and HCV coinfected patients. Hepatology 1999; 30:1054-1058.
24. Moyle G. Hyperlactatemia and lactic acidosis during antiretroviral therapy: causes, management and possible etiologies. AIDS Rev 2001; 3:150-156.
25. Martínez E, Mocroft A, García-Viejo MA, Pérez-Cuevas J, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357:592-598.
26. EASL Panel. EASL consensus statement on hepatitis C. J Hepatol 1999; 30:956-961.
27. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16:813-828.
28. DHHS. Updated guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, http://www.hivatis.org/guidelines/Accessed 4 February 2002.